[The role of the brain monoaminergic systems in the anti-alcohol action of dermorphin and the delta-sleep peptide].
Gromova. E A EA; Bobkova. N V NV; Plakkhinas. L A LA; Deĭgin. V I VI; Iarova. E P EP
Key Findings
- Both dermorphin and DSIP (200 mg/kg, injected daily) sharply reduced voluntary alcohol consumption in rats for 3‑4 weeks after treatment.
- The anti‑alcohol effect was accompanied by a significant decrease in hypothalamic serotonin and its metabolite 5‑HIAA.
Practical Outcomes
- While the results hint that targeting serotonin with these peptides could help curb alcohol cravings, the high dose and injection route used in rats are far from practical for humans. Biohackers should view this as early‑stage evidence that may inspire future oral or low‑dose formulations, but more research is needed before any real‑world protocol can be recommended.
Summary
In a rat study, two brain‑active peptides—dermorphin and the delta‑sleep peptide (DSIP)—were given daily for ten days and caused the animals to drink less alcohol for several weeks. The drop in drinking was linked to lower serotonin levels in a brain region that controls hormone release.
Abstract
The effects of dermorphin and DSIP were studied in male Wistar rats chronically treated with ethanol. Both peptides (200 mg/kg, i. p., daily during 10 days) significantly reduced volitional alcohol intake for 3-4 weeks. These effects were associated with a marked decrease in serotonin and its metabolite 5-HIAA levels in the hypothalamus. The findings suggest that antialcoholic effects of both peptides are actualized through mechanisms involving serotoninergic system of the brain.
Study Information
pubmed
1989